Resonance Health is a healthcare company listed on the Australian Stock Exchange (ASX:RHT). Resonance Health provides quantitative MRI based technologies for the diagnosis and monitoring of human disease. Accurate imaging end points are increasingly used in clinical trials, providing quantitative and direct evidence for regulatory submissions.
Resonance Health's image analysis laboratory provides quality certified central image analysis services to the clinical community and to clinical trials.
FerriScan® was the first product brought to market and provides an accurate non-invasive assessment of liver iron, largely removing the need for a liver biopsy in many patients with iron overload conditions.
HepaFat-Scan® gained FDA clearance in December 2013 for the measurement of fatty liver and development of an MRI based method to assess liver fibrosis continues as part of the Company's focus on developing diagnostic products to address liver disease.
Registered Office and Principal Place of Business:
141 Burswood Road
Burswood Western Australia 6100
Postal Address
PO Box 71
Burswood Western Australia 6100
ABN
96 006 762 492
Contact details:
T +61 8 9286 5300
F +61 8 9286 5399
E info@resonancehealth.com
W www.resonancehealth.com
Investor Enquiries:
Mitchell Wells
T +61 8 9286 5300
E info@resonancehealth.com
Auditors
HLB Mann Judd
Level 4
130 Stirling Street
Perth Western Australia 6000
Resonance Health’s Principal Share Registry:
Advanced Share Registry Services
110 Stirling Hwy
Nedlands Western Australia 6009
T +61 8 9389 8033
F +61 8 9262 3723
Corporate Governance
- Corporate Policy Manual
- Corporate Governance Statement 2021
- Board Charter
- Communication Charter
- Continuous Disclosure Policy
- Securities Trading Policy
- Whistleblower Policy
- Audit and Risk Committee Charter
- Nomination and Remuneration Committee Charter
- RHT Code of Conduct
- Constitution of Resonance Health (as approved at the Annual General Meeting on 24th Nov 2016)